Gonza´lez-Sab´ın et al.
biocatalytic and nonenzymatic processes: the stereospecific
transformation of (()-trans-2-(N,N-dialkylamino)cyclopentanols
into (()-trans-cyclopentane-1,2-diamines and the subsequent
enzymatic resolution are the key steps. Some of the diamines
(Figure 1) were also chosen for their pharmacological properties;
1b is an analogue of the anticholinergic vesamicol,15 and 1c is
precursor of CCR-3 chemokine receptor antagonists.16 In
addition, diamines 1a and 1d bear easily removable substituents,
which allowed us to differ both amino groups for the modular
synthesis of a novel set of derivatives with potential synthetic
utility.
FIGURE 1. Selected trans-N,N-dialkylcyclopentane-1,2-diamines.
Results and Discussion
Synthesis of Racemic Diamines 1a-d. Diamines (()-1a-d
(Scheme 1) were prepared from the analogous (()-trans-2-(N,N-
dialkylamino)cyclopentanols (2a-d)17 following the strategy
developed for the synthesis of racemic N,N-disubstituted
cyclohexane-1,2-diamines.18 Thus, the one-pot treatment of (()-
2a-d with mesyl chloride and subsequently with aqueous
ammonia afforded trans-diamines (()-1a-d as the only product,
in very good yields (>85%). We expected this reaction to
proceed via an aziridinium intermediate as in the case of the
cyclohexane-1,2-diamines. Once the mesylation of alcohol takes
place, the resulting mesyl derivative would experience an
intramolecular SN2 reaction with the formation of the meso-
aziridinium ion (Az), which would be attacked by the ammonia
leading to the final trans-diamine (Scheme 1).
nation of prochiral ketones,9 or epoxidation and cyclopropana-
tion of olefins.10 In contrast, applications of nonracemic trans-
cyclopentane-1,2-diamine still remain almost unexplored due
to the complexity of the reported syntheses and their poor yields.
Since the pioneering work of Toftlund and Pedersen,11 only a
few approaches have appeared for this compound, and in
general, the enantiopure diamine is only obtained after multistep
sequences with low overall yields.12
Continuing with our interest in the synthesis of optically active
1,2-diamines, and encouraged both by the scarcity of reported
syntheses of cyclopentane-1,2-diamine and by the promising
utility of some of its derivatives as chiral ligands13 and
precursors of improved peptide nucleic acids (PNAs),14 we
focused our research on the development of efficient routes for
preparing optically active N,N-disubstituted trans-cyclopentane-
1,2-diamines. The strategy described in this article combines
SCHEME 1. Preparation of Racemic Diamines 1a-d
(7) For an excellent review, see: (a) Bennani, Y. L.; Hanessian, S. Chem.
ReV. 1997, 97, 3161-3196. For some recent examples of the utility of trans-
cyclohexane-1,2-diamine derivatives in asymmetric catalysis, see: (b)
Huang, H.; Jacobsen, E. N. J. Am. Chem. Soc. 2006, 128, 7170-7171. (c)
Fuerst, D. E.; Jacobsen, E. N. J. Am. Chem. Soc. 2005, 127, 8964-8965.
(d) Evans, D. A.; Seidel, D. J. Am. Chem. Soc. 2005, 127, 9958-9959. (e)
Aoyama, H.; Tokunaga, M.; Kiyosu, J.; Iwasawa, T.; Obora, Y.; Tsuji, Y.
J. Am. Chem. Soc. 2005, 127, 10474-10475. For some examples of
macrocyclic receptors containing the trans-cyclohexane-1,2-diamine unit,
see: (f) Pan, Z.; Still, W. C. Tetrahedron Lett. 1996, 37, 8699-8702. (g)
Alfonso, I.; Rebolledo, F.; Gotor, V. Chem.-Eur. J. 2000, 6, 3331-3338.
(h) Alfonso, I.; Dietrich, B.; Rebolledo, F.; Gotor, V.; Lehn, J.-M. HelV.
Chim. Acta. 2001, 84, 280-295. (i) Lee, K. H.; Lee, D. H.; Hwang, S.;
Lee, O. S.; Chung, D. S.; Hong, J.-I. Org. Lett. 2003, 5, 1431-1433.
(8) (a) Garc´ıa, C.; Walsh, P. J. Org. Lett. 2003, 5, 3641-3644. (b) Li,
H.; Walsh, P. J. J. Am. Chem. Soc. 2004, 126, 6538-6539.
(9) Palmer, M. J.; Wills, M. Tetrahedron: Asymmetry 1999, 10, 2045-
2061.
As the configuration of cyclopentane derivatives cannot be
assigned from values of coupling constants, the trans configu-
ration of these diamines 1a-d was assigned by comparison with
the configurationally known trans-amino alcohols 2a-d.17
Accordingly, we carried out NOE measures on the trans-amino
alcohol 2a and the acetamide 3a, obtained by acetylation of 1a
(with unknown relative configuration).19 Two signals, OH (or
NH) and H-2, were irradiated for both compounds, and the NOE
enhancements of the other two depicted signals (Figure 2) were
(10) McGarrigle, E. M.; Gilheany, D. G. Chem. ReV. 2005, 105, 1563-
1602.
(11) Optically active trans-cyclopentane-1,2-diamine was prepared for
the first time by applying the classical recrystallization with tartaric acid.
However, high enantiomeric excesses were obtained only after several
recrystallization cycles, which led to a low overall yield: Toftlund, H.;
Pedersen, E. Acta Chem. Scand. 1972, 26, 4019-4030.
(12) (a) Ongeri, S.; Aitken, D. J.; Husson, H.-P. Synth. Commun. 2000,
30, 2593-2597. (b) Luna, A.; Alfonso, I.; Gotor, V. Org. Lett. 2002, 4,
3627-3629. (c) de Parrodi, C. A.; Walsh, P. J. Synlett 2004, 13, 2417-
2420. (d) Myers, M. C.; Witschi, M. A.; Larionova, N. V.; Franck, J. M.;
Haynes, R. D.; Hara, T.; Grajkowski, A.; Apella, D. H. Org. Lett. 2003, 5,
2695-2698.
(13) (a) Dominguez, B.; Hodnett, N. S.; Lloyd-Jones, G. C. Angew.
Chem., Int. Ed. 2001, 40, 4289-4291. (b) Gouin, S. G.; Gestin, J.-F.; Joly,
K.; Loussouarn, A.; Reliquet, A.; Meslin, J. C.; Deniaud, D. Tetrahedron
2002, 58, 1131-1136. (c) Hoffmann, R. W.; Klute, W.; Dress, R. K.;
Wenzel, A. J. Chem. Soc., Perkin Trans. 2 1995, 1721-1726. (d) Daly,
A. M.; Gilheany, D. G. Tetrahedron: Asymmetry 2003, 14, 127-137.
(14) (a) Pokorski, J. K.; Witschi, M. A.; Purnell, B. L.; Appella, D. H.
J. Am. Chem. Soc. 2004, 126, 15067-15073. (b) Pokorski, J. K.; Nam,
J.-M.; Vega, R. A.; Mirkin, C. A.; Appella, D. H. Chem. Commun. 2005,
2055-2056.
FIGURE 2. Selected signals of 2a and 3a for NOE experiments.
compared in each case. Irradiation of the H-2 signal of 2a causes
a strong NOE on the OH signal, which increased much more
than that of H-1, as expected due to the trans configuration.
The same effect was observed when we irradiated the H-2 signal
of the acetamide 3a. Moreover, the NOE enhancement of both
(15) Marshall, I. G.; Parsons, S. M. Trends Neurosci. 1987, 10, 174-
177.
(16) Du, B.; Daisy, J. J. PCT Int. Appl. 2003, WO 2003022799 A1;
Chem. Abstr. 2003, 138, 254963.
1310 J. Org. Chem., Vol. 72, No. 4, 2007